RESUMO
Hypertriacylglyceridemia and low HDLc combination is one of the most common lipidic abnormalities. Thus, the aim of this study was to determine the effects of Ciprofibrate on patients with Frederickson's Type IV dyslipidemia phenotype. 75 patients with type IV dyslipidemia were assigned at random to one of two therapeutic options: Group A, AHA diet and physical activity and B, AHA diet, physical activity and Ciprofibrate 100 mg daily for 12 weeks. All patients underwent lipidic profile quantification before and after therapeutic intervention. Ciprofibrate treatment group exhibited significantly reduction in total cholesterol (-14,2 per cent vs. -4,8 per cent; p<0,02), triglycerides (-38 per cent vs. -21,6 per cent; p<0,007), VLDLc (-38 per cent vs. -21,6 per cent; p<0,007) Non-HDLc (-20,5 per cent vs. -7,1 per cent; p<0,007) and total cholesterol to HDLc ratio (-25,6 per cent vs. -9,4 per cent; p<0,01) when comparing with diet/physical activity group. HDLc showed an important increase in Ciprofibrate group when contrast with diet/physical activity group (+25 per cent vs. +9,6 per cent, p<0,02). Ciprofibrate treatment effectively reduced triglycerides rich particles and Non-HDLc and significantly increased HDLc, proving it's usefulness in low HDLc syndrome and type IV Frederickson's hyperlipidemia